Notice2022-04829
Prospective Grant of an Exclusive Patent License: NCGC00413972 and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core for the Treatment or Prevention of Cancers Expressing the Mannose Receptor CD206, Including Both Solid Tumors and Hematological Malignancies
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
March 8, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patent Applications listed in the Supplementary Information section of this notice to Macala Bio, Inc. located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 45 (Tuesday, March 8, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 45 (Tuesday, March 8, 2022)]
[Notices]
[Page 12968]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-04829]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: NCGC00413972
and Its Related Analogs Consisting of an Imidazo-Pyrazine Scaffold Core
for the Treatment or Prevention of Cancers Expressing the Mannose
Receptor CD206, Including Both Solid Tumors and Hematological
Malignancies
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patent Applications listed in the
Supplementary Information section of this notice to Macala Bio, Inc.
located in 1000 NW Wall Street, Suite 220, Bend, OR 97703.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before March 23, 2022 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Eric Cheng, Ph.D., Licensing and Patenting
Manager at (240)-276-5530 or <a href="/cdn-cgi/l/email-protection#b4d1c6ddd79ad7dcd1dad386f4dadddc9ad3dbc2"><span class="__cf_email__" data-cfemail="01647368622f6269646f6633416f68692f666e77">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
United States Provisional Patent Application No. 62/950,488, filed
19 December 2019 and entitled ``CD206 Modulators Their Use And Methods
For Preparation'' [HHS Reference No. E-105-2019/0-US-01];
PCT Patent Application PCT/US2020/065238, filed 16 December 2020
and entitled ``CD206 Modulators Their Use And Methods For Preparation''
[HHS Reference No. E-105-2019-0-PCT-02].
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: NCGC00413972 and its related
analogs consisting of an imidazo-pyrazine scaffold core for the
treatment or prevention of cancers expressing the mannose receptor
CD206, including both solid tumors and hematological malignancies.
This technology discloses immunotherapy drugs, and to compounds
that modulate CD206 as well as their use and methods for preparation.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: March 2, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2022-04829 Filed 3-7-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on March 8, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.